CTKB Stock Analysis: Cytek Biosciences | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 764m USD | 12M Return: 20.2% | US23285D1090 | Charts, Fundamentals & Technical Analysis

Flow Cytometers, Imaging Cytometers, Cell Analyzers, Reagents
Total Rating 47
Safety 80
Buy Signal 1.27
Health Care Equipment
Sub-Industry Rotation: -2.2
Market Cap: 764M
Avg Turnover: 7.14M
Risk 3d forecast
Volatility62.2%
VaR 5th Pctl10.1%
VaR vs Median-1.47%
Reward TTM
Sharpe Ratio0.54
Rel. Str. IBD96
Rel. Str. Peer Group87.2 pctl
Character TTM
Beta0.423
Beta Downside0.557
Hurst Exponent0.516
Choppyness65.3%
Drawdowns 3y
Max DD74.55%
CAGR/Max DD-0.04
CAGR/Mean DD-0.07
EPS (Earnings per Share) EPS (Earnings per Share) of CTKB over the last years for every Quarter: "2021-09": 0.01, "2021-12": 0.03, "2022-03": -0.02, "2022-06": 0.03, "2022-09": 0.04, "2022-12": 0.06, "2023-03": -0.05, "2023-06": -0.03, "2023-09": -0.01, "2023-12": 0.04, "2024-03": -0.01, "2024-06": -0.01, "2024-09": 0.06, "2024-12": 0.1208, "2025-03": -0.03, "2025-06": -0.01, "2025-09": -0.04, "2025-12": -0.04, "2026-03": -0.1, "2026-06": -0.09, "2026-09": -0.05,
Last SUE: 1.40
Qual. Beats: 1
Revenue Revenue of CTKB over the last years for every Quarter: 2021-09: 34.376, 2021-12: 38.894, 2022-03: 35.064, 2022-06: 40.159, 2022-09: 40.477, 2022-12: 48.336, 2023-03: 37.088, 2023-06: 49.693, 2023-09: 48, 2023-12: 58.233, 2024-03: 44.86, 2024-06: 46.617, 2024-09: 51.5, 2024-12: 57.476, 2025-03: 41.457, 2025-06: 45.602, 2025-09: 52.293, 2025-12: 62.141, 2026-03: 44.135, 2026-06: 48.14, 2026-09: 53.229,
Rev. CAGR: 1.75%
Rev. Trend: 71.1%
Last SUE: 0.13
Qual. Beats: 0

Warnings

High Debt/EBITDA With Thin Interest Coverage
High Debt While Negative Cash Flow
Interest Coverage Ratio Critical

Tailwinds

Rs Leader
Idiosyncratic Leader
Early Tailwind
Confidence

Seasonality 5.3 years of data, until 10/2026

Jan -4.9% 0
Feb -7.7% 0
Mar -4.0% 14
Apr -3.5% 0
May -8.9% 14
Jun +13.0% 40
Jul +20.1% 14
Aug +1.5% 0
Sep +2.7% 5
Oct +1.6% 5
Nov +42.5% 0
Dec -12.1% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: CTKB Cytek Biosciences

Cytek Biosciences, Inc. (NASDAQ: CTKB) is a cell analysis solutions company that develops and sells flow cytometry instruments, imaging flow cytometers, reagents, and software used in biomedical research and clinical applications. Its product portfolio spans the Cytek Aurora, Northern Lights, and Aurora EVO spectral flow cytometry systems, the Amnis ImageStream imaging flow cytometers, and the Guava Muse and easyCyte flow cytometers, along with cFluor reagent kits, the Orion reagent cocktail preparation system, and SpectroFlo acquisition and analysis software. The company markets its offerings under the Amnis and Guava brand names and serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations (CROs).

The company distributes products through a direct sales force in North America, Europe, China, and the broader Asia-Pacific region, and through distributors in parts of Europe, Latin America, and the Middle East. Founded in 1992 and headquartered in Fremont, California, Cytek was formerly known as Cytoville, Inc. before adopting its current name in August 2015, and completed its IPO in July 2021.

As a life sciences tools provider in the healthcare equipment sub-industry, Cytek operates a combined razor-and-blade business model, selling capital instruments while generating recurring revenue from consumables such as cFluor antibody reagents and reagent kits. Flow cytometry is a widely adopted technique for analyzing cell characteristics in immunology, oncology, and drug discovery research.

Headlines to Watch Out For
  • Reagent revenue growth drives recurring installed base expansion
  • China sales exposure creates geopolitical and currency risk
  • Competition from BD and Beckman Coulter pressures flow cytometry pricing
  • Biotech R&D spending softness pressures instrument order growth
Piotroski VR-10 (Strict) 2.0
Net Income: -81.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA -1.83 > 1.0
NWC/Revenue: 141.6% < 20% (prev 159.2%; Δ -17.59% < -1%)
CFO/TA -0.01 > 3% & CFO -6.59m > Net Income -81.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.46 > 1.5 & < 3
Outstanding Shares: last quarter (130.4m) vs 12m ago 2.20% < -2%
Gross Margin: 54.75% > 18% (prev 53.46%; Δ 1.29% > 0.5%)
Asset Turnover: 44.13% > 50% (prev 39.77%; Δ 4.36% > 0%)
Interest Coverage Ratio: -25.15 > 6 (EBIT TTM -38.4m / Interest Expense TTM 1.53m)
Altman Z'' 5.46
A: 0.66 (Total Current Assets 378.9m - Total Current Liabilities 85.0m) / Total Assets 446.1m
B: -0.31 (Retained Earnings -138.9m / Total Assets 446.1m)
C: -0.08 (EBIT TTM -38.4m / Avg Total Assets 470.5m)
D: 2.58 (Book Value of Equity 321.4m / Total Liabilities 124.8m)
Altman-Z'' = 5.46 = AAA
Beneish M -3.36
DSRI: 0.93 (Receivables 60.8m/61.7m, Revenue 207.6m/196.8m)
GMI: 0.98 (GM 53.46% / 54.75%)
AQI: 0.52 (AQ_t 0.08 / AQ_t-1 0.16)
SGI: 1.05 (Revenue 207.6m / 196.8m)
TATA: -0.17 (NI -81.2m - CFO -6.59m) / TA 446.1m)
Beneish M = -3.36 (Cap -4..+1) = AA
What is the price of CTKB shares?

As of November 20, 2026, the stock is trading at USD 6.32 with a total of 2,180,769 shares traded. Over the past week, the price has changed by +14.49%, over one month by +20.38%, over three months by +34.47% and over the past year by +20.15%.

Current recommended Stop Loss: 5.90 (which is 6.6% or 1.3 ATR below the current price).

Is CTKB a buy, sell or hold?

Cytek Biosciences has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CTKB.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CTKB price?
Analysts Target Price 6.5 2.8%
Cytek Biosciences (CTKB) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 763.8m (763.8m USD * 1.0 USD.USD)
P/E Forward = 370.3704
P/S = 3.6783
P/B = 2.3768
Revenue TTM = 207.6m USD
EBIT TTM = -38.4m USD
EBITDA TTM = -26.5m USD
Long Term Debt = 99.0k USD (from longTermDebt, last quarter)
Short Term Debt = 11.8m USD (from shortTermDebt, last quarter)
Debt = 40.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 16.2m
Net Debt = -215.0m USD (calculated: Debt 40.9m - CCE 255.9m)
Enterprise Value = 548.8m USD (763.8m + Debt 40.9m - CCE 255.9m)
Interest Coverage Ratio = -25.15 (Ebit TTM -38.4m / Interest Expense TTM 1.53m)
EV/FCF = -40.70x (Enterprise Value 548.8m / FCF TTM -13.5m)
FCF Yield = -2.46% (FCF TTM -13.5m / Enterprise Value 548.8m)
FCF Margin = -6.49% (FCF TTM -13.5m / Revenue TTM 207.6m)
Net Margin = -39.10% (Net Income TTM -81.2m / Revenue TTM 207.6m)
Gross Margin = 54.75% ((Revenue TTM 207.6m - Cost of Revenue TTM 94.0m) / Revenue TTM)
Gross Margin QoQ = 58.63% (prev 58.87%)
Tobins Q-Ratio = 1.23 (Enterprise Value 548.8m / Total Assets 446.1m)
Interest Expense / Debt = 3.73% (Interest Expense 1.53m / Debt 40.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -30.4m (EBIT -38.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.46 (Total Current Assets 378.9m / Total Current Liabilities 85.0m)
Debt / Equity = 0.13 (Debt 40.9m / totalStockholderEquity, last quarter 321.4m)
 Debt / EBITDA = 8.12 (negative EBITDA) (Net Debt -215.0m / EBITDA -26.5m)
 Debt / FCF = 15.94 (negative FCF - burning cash) (Net Debt -215.0m / FCF TTM -13.5m)
 Total Stockholder Equity = 328.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.26% (Net Income -81.2m / Total Assets 446.1m)
RoE = -24.74% (Net Income TTM -81.2m / Total Stockholder Equity 328.2m)
RoCE = -11.71% (EBIT -38.4m / Capital Employed (Equity 328.2m + L.T.Debt 99.0k))
 RoIC = -8.37% (negative operating profit) (NOPAT -30.4m / Invested Capital 362.6m)
 WACC = 6.86% (E(763.8m)/V(804.7m) * Re(7.07%) + D(40.9m)/V(804.7m) * Rd(3.73%) * (1-Tc(0.21)))
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -36.14 | Cagr: -0.37%
 [DCF] Fair Price = unknown (Cash Flow -13.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.40 | # QB: 1
Revenue Correlation: 71.12 | Revenue CAGR: 1.75% | SUE: 0.13 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.08 | Chg30d=+27.27% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.29 | Chg30d=+16.49% | Revisions=-40% | GrowthEPS=+44.9% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=-0.18 | Chg30d=+27.64% | Revisions=-50% | GrowthEPS=+36.0% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -67% (up=0, down=6)